Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited · Author: FormBlends Editorial
Key Takeaways
- Scott Disick has not publicly confirmed or denied GLP-1 medication use as of May 2026; no on-the-record statement has been located
- Visible facial volume loss in his 2023-2025 photos is real and substantial, but appearance alone is not diagnostic of medication use
- The Kardashian-Jenner extended family has uniformly avoided confirmation of GLP-1 use; multiple members have denied
- The "Ozempic face" label is a popular term, not a clinical diagnosis; facial fat pad reduction occurs with any meaningful weight loss
- Disick's visible pattern (gradual loss over 18-24 months, no public mentions of nausea or food aversion) is consistent with multiple explanations including but not limited to GLP-1 therapy
Direct answer
Scott Disick has neither confirmed nor denied using a GLP-1 medication. His visibly gaunt facial appearance since 2023 has fueled speculation, but the same facial changes occur with any meaningful weight loss, and his behavioral patterns do not uniquely fingerprint a medication cause. Without a public statement or medical records, the honest answer is that we do not know.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- What Scott Disick has and has not said
- The photographic timeline: 2020 through 2025
- What "Ozempic face" actually means clinically
- Why facial volume loss is not method-specific
- The Kardashian-Jenner family disclosure pattern
- What would constitute evidence of GLP-1 use
- Alternative explanations with equal or better fit
- How dermatologists read facial volume changes
- The decision framework: what does the speculation tell you about your own choices
- The contrary view: why the GLP-1 hypothesis is reasonable
- FAQ
- Sources
What Scott Disick has and has not said
As of May 2026, no on-the-record statement from Scott Disick about GLP-1 medications, Ozempic, semaglutide, or tirzepatide has been located in mainstream press archives, podcast appearances, or social media. He has addressed his weight and health indirectly on episodes of The Kardashians (Hulu, ongoing) but has not specified any medication.
In a March 2024 episode of The Kardashians, Disick discussed back pain and physical limitations after a 2022 car accident. He referenced lifestyle changes including dietary modification and physical therapy. The medication question did not come up on camera. No clip of him directly addressing GLP-1 rumors has surfaced as of this writing.
His Instagram (@letthelordbewithyou) has been sporadic about health topics. Posts in 2023-2025 focus on his children, his businesses (Talentless apparel), and lifestyle content. He has not posted about weight loss, diet, or medication.
The silence itself is significant in two directions. It rules out denial (he has not said he isn't using GLP-1 medications) and it rules out confirmation (he has not said he is). Speculation based on this silence is exactly that: speculation.
The photographic timeline: 2020 through 2025
The visible change in Disick's appearance is not in dispute. Paparazzi archives and public appearances show a clear progression.
| Period | Visible state | Public context |
|---|---|---|
| 2020-2021 | Heavier facial fullness; visible jaw padding; thicker neck contour | Pre-accident; active on Kourtney & Khloe Take the Hamptons related content |
| 2022 | Mid-range appearance; some weight gain reported around the time of his March 2022 car accident | Car accident on PCH; reports of opioid pain management following surgery |
| Mid-2023 | Beginning of visible facial slimming; cheek hollowing first appears in paparazzi photos | Speculation begins on TikTok and Twitter (X); "Ozempic face" articles published in Page Six and Daily Mail |
| 2024 | Pronounced facial volume loss; temple hollowing visible; jawline more defined | Hamptons appearances draw further commentary; The Kardashians Season 5 airs |
| 2025 | Sustained gaunt appearance; no apparent reversal | Limited public appearances; minimal direct media engagement |
Two features of this timeline are worth noting. First, the change is gradual, occurring over roughly 18-24 months from initial visible slimming through current state. Second, the change is sustained rather than fluctuating, which suggests either continued caloric deficit, continued medication use, or persistent underlying cause.
The gradual pattern is consistent with GLP-1 therapy. It is also consistent with several non-medication explanations including persistent dietary restriction, ongoing health issues from his 2022 accident, or behavioral changes following sobriety work.
What "Ozempic face" actually means clinically
The term "Ozempic face" entered popular discourse in January 2023 via a New York Times article quoting Manhattan dermatologist Paul Jarrod Frank. It is a popular descriptor, not a clinical diagnosis. No version of the term appears in the International Classification of Diseases (ICD-11), the Diagnostic and Statistical Manual, or peer-reviewed dermatology literature as a distinct entity.
What clinicians actually see is volume loss in the midface, temples, and periorbital region following weight reduction. The mechanism is well understood: subcutaneous fat decreases proportionally with total adipose mass. The face contains multiple fat compartments (nasolabial, malar, buccal, temporal, periorbital), each of which loses volume when overall fat stores decline.
A 2019 study in Aesthetic Surgery Journal (Gierloff et al.) used computed tomography to track midfacial fat compartments across age and weight groups. The findings: facial fat pads decrease in volume with both aging and weight loss, with weight-related change being more reversible than age-related change. The study did not identify any signature pattern specific to medication-induced versus diet-induced weight loss.
A 2022 follow-up in Plastic and Reconstructive Surgery (Rohrich et al.) examined 156 patients who lost 15+ pounds through bariatric surgery, GLP-1 medication, or diet alone. Facial volume reduction correlated with total pounds lost (r = 0.76, p < 0.001), not with method. In other words, the face does not look different depending on how you lost the weight. It looks different depending on how much weight you lost.
Why facial volume loss is not method-specific
The "Ozempic face" framing implies that GLP-1 medications produce a distinctive facial pattern. The clinical evidence does not support this.
Several factors influence the prominence of facial volume loss after weight reduction:
- Total magnitude of loss. A 15-pound loss produces visible but mild facial change. A 40-pound loss produces dramatic change. Disick's apparent loss falls roughly in the middle of this range.
- Speed of loss. Faster loss gives soft tissue less time to retract, resulting in more visible skin laxity. Rapid loss (3+ pounds per week) tends to produce more pronounced facial change.
- Age. Patients over 40 have less skin elasticity and more apparent volume loss. Disick is 42 (born May 26, 1983), placing him in the bracket where facial fat redistribution accelerates regardless of weight.
- Baseline fat distribution. Some bodies hold more fat in the face proportionally. These individuals show more facial change per pound lost.
- Hydration and sleep status. Chronic dehydration and sleep deprivation produce facial puffiness that resolves when corrected, sometimes mimicking weight loss.
The STEP 1 trial (Wilding et al., New England Journal of Medicine 2021) reported facial volume loss in case narratives but did not isolate it as a distinct adverse event. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) for tirzepatide similarly did not categorize "Ozempic face" as a side effect. It is a cosmetic consequence of fat loss, not a medication-specific mechanism.
The implication for Disick: his facial change is real, but pointing at it as proof of GLP-1 use is the equivalent of pointing at sunburn as proof of a specific sunscreen brand. The visible effect could come from many causes.
The Kardashian-Jenner family disclosure pattern
Disick is not biologically a Kardashian or Jenner. He is the ex-partner of Kourtney Kardashian and father of three of her children (Mason, Penelope, Reign). He remains in the family orbit through co-parenting and through his presence on The Kardashians. His public-facing patterns track closely with the extended family's.
The family's pattern with respect to GLP-1 medications is consistent: deny, deflect, or stay silent. No member has confirmed use.
| Family member | Public position on GLP-1 | Source |
|---|---|---|
| Kris Jenner | Has not addressed on the record | No located statement |
| Kim Kardashian | Denied; attributes weight changes to The Kardashians training and diet | Multiple interviews 2022-2024 |
| Kourtney Kardashian | Has not addressed; has discussed Poosh wellness content broadly | No located statement |
| Khloe Kardashian | Denied; attributes changes to Pilates, weight training, dietary modification | 2023 Daily Mail response, later social media posts |
| Kylie Jenner | Denied; has addressed weight rumors via social media | 2023-2024 social media posts |
| Kendall Jenner | Has not addressed on the record | No located statement |
| Scott Disick | Has not addressed on the record | No located statement |
The pattern matters because it tells you what kind of disclosure to expect. Celebrities who later confirmed GLP-1 use (Oprah Winfrey in March 2024, Sharon Osbourne in 2023, Serena Williams in August 2025) generally moved through three phases: silence, then non-denial denial, then confirmation. The Kardashian-Jenner pattern has been more consistently in the silence-or-denial mode without progressing to confirmation.
What this does not tell you: whether anyone in the family actually uses GLP-1 medications. The disclosure pattern could reflect non-use, or it could reflect a coordinated PR strategy. Without records, we cannot know.
What would constitute evidence of GLP-1 use
If you want to think about this case carefully rather than reactively, here is what would qualify as evidence:
Direct evidence (would settle the question):
- Disick's own public statement confirming use
- Prescription records (private; not available)
- Insurance claims data (private; not available)
- A clinician on record confirming treatment (would breach HIPAA)
Strong circumstantial evidence (would shift the probability significantly):
- Discussion of GI side effects, nausea, or "food noise" reduction in interviews or social posts
- Visible injection site marks in paparazzi photos (occasionally captured for other celebrities)
- Reports from people in his orbit (family members, ex-partners, staff) speaking on record
- Tabloid sourcing from named pharmacy or telehealth platform employees (rare and ethically problematic)
Weak circumstantial evidence (suggestive but insufficient):
- Visible facial volume loss
- Visible body composition change
- Temporal correlation with GLP-1 cultural awareness
- Reports from unnamed "sources close to" the celebrity
The case against Disick currently rests entirely on weak circumstantial evidence. The facial change is real. The temporal correlation with the cultural wave is real. Everything else is inference.
Alternative explanations with equal or better fit
Several non-GLP-1 explanations fit the visible pattern. Some fit better than the GLP-1 hypothesis.
Explanation 1: Recovery from the March 2022 car accident and associated opioid exposure.
Disick was hospitalized following a vehicle rollover in March 2022. Reports referenced surgery and pain management with opioids. Opioid use is associated with weight changes in both directions: weight gain in the acute treatment phase (food as comfort, decreased activity) and weight loss in withdrawal or tapering phases (appetite suppression, GI distress). The timing of his visible slimming (mid-2023, roughly 12-15 months post-accident) is consistent with a recovery and tapering window.
Explanation 2: Sobriety work and behavioral change.
Disick has been publicly open about his history with substance use and has discussed sobriety on multiple episodes of The Kardashians. Sustained sobriety often produces gradual weight changes, including weight loss when alcohol-related caloric intake is removed (alcoholic beverages contribute substantial empty calories) or weight gain when sugar substitution occurs. Sustained sobriety with active rehabilitation work is consistent with gradual, sustained weight change.
Explanation 3: Age-related fat redistribution.
Disick turned 40 in May 2023. The third and fourth decades of life produce predictable changes in fat distribution: visceral fat increases, subcutaneous fat redistributes, facial fat pads descend. A 2018 study in Aging Cell tracked body composition across age groups and found measurable midface volume loss beginning around age 40, with acceleration through the late 40s. Disick's visible change pattern is partially attributable to chronological aging, independent of any intentional intervention.
Explanation 4: Stress and reduced appetite.
The 2022-2025 period included his accident recovery, custody negotiations around his three children, and public scrutiny of his relationship choices. Sustained stress produces hypothalamic-pituitary-adrenal axis activation that suppresses appetite in some individuals. Combined with reduced physical activity due to chronic pain, this pattern could produce gradual weight loss.
Explanation 5: Intentional dietary restriction.
The simplest explanation: he decided to lose weight and did so through dietary intervention. People do this. The intervention does not have to be exotic to produce visible results.
The GLP-1 hypothesis is one possibility among at least five plausible alternatives. None of these is mutually exclusive with the others; the actual pattern likely involves multiple contributing factors. The clinical reality is that public figures, like all people, rarely change for one isolated reason.
How dermatologists read facial volume changes
When a patient presents in a dermatology or aesthetic medicine consultation with facial volume loss, the clinician's diagnostic process focuses on patterns rather than single signs.
The dermatologic assessment includes:
- Pattern of volume loss. Generalized versus regional. Symmetric versus asymmetric. Acute (over weeks) versus chronic (over months to years).
- Skin quality. Elasticity (recovery from pinch test), thickness, hydration, evidence of photoaging. Rapid weight loss in older patients often produces visible skin laxity that gradual loss does not.
- Underlying skeletal structure. Bone loss in the maxilla, mandible, and orbital rim contributes to apparent volume loss independent of soft tissue.
- Patient interview. Recent weight change, medication history (including GLP-1, stimulants, thyroid medications), illness, sleep patterns, alcohol and substance use, stress levels.
- Photographic comparison. Year-over-year comparison from the patient's own records, not paparazzi photos, to establish trajectory.
Without that workup, calling someone's appearance "Ozempic face" is a guess. A reasonably trained clinician looking at Disick's progression in paparazzi photos can identify the volume loss, estimate the magnitude of weight change required to produce it, and identify possible mechanisms. None of that produces a definitive medication attribution.
The proper framing in clinical practice: "Patient shows visible mid-face and temporal volume loss consistent with 20-30 pounds of weight reduction over 18-24 months. Differential includes intentional dietary restriction, pharmacotherapy (GLP-1 agonists, stimulants), illness, or behavioral changes. History required for further specification."
The decision framework: what does the speculation tell you about your own choices
Whether Disick is on a GLP-1 medication is interesting gossip. It is not relevant to your medical decision making.
If you are considering GLP-1 therapy because you see Disick's facial change and want similar body composition results:
- The facial change is a side effect of weight loss, not the goal of treatment
- If you do not meet FDA criteria for GLP-1 therapy (BMI 30+, or BMI 27+ with qualifying comorbidities), the medication is not appropriate
- The visible facial change you are responding to may be partially age-related and not reproducible through medication alone
- The risk-benefit calculation for medication should weigh metabolic outcomes, not appearance outcomes
If you are worried about developing "Ozempic face" yourself while on therapy:
- Facial volume loss correlates with total weight loss, not with the specific medication you use
- Maintaining adequate protein intake (1.0-1.2 g/kg body weight or higher) and resistance training preserves lean mass and can partially offset visible cosmetic change
- If facial change is unacceptable, dermatologic intervention (hyaluronic acid fillers, biostimulatory injectables, fat grafting) is available and does not require discontinuing therapy
- Slower titration produces more gradual facial change, which is generally better tolerated cosmetically
If you are concerned about a friend or family member you think might be using GLP-1 medications based on visible facial changes:
- Their medication decisions are not your business unless they have invited you in
- If you are worried about their health or wellbeing, ask about how they are doing, not about what medications they take
- Facial changes have many causes, including ones (illness, mental health, stress) that warrant compassion rather than assumption
If you are evaluating telehealth platforms for your own care:
- Celebrity speculation should not drive your platform choice
- Evaluate platforms on clinical oversight quality, pharmacy network, refill responsiveness, and side-effect support
- The platform a celebrity uses (if known) reflects their access and PR considerations, not necessarily clinical fit for you
The contrary view: why the GLP-1 hypothesis is reasonable
The case for skepticism about the "we don't know" framing rests on context.
Argument 1: The cultural moment matters.
Disick's visible changes coincide exactly with the peak cultural availability and discussion of GLP-1 medications (2023-2025). The timing alignment is striking. In a different decade, the same facial change might be attributed to stress, sobriety, or aging. The fact that GLP-1 medications became culturally dominant during the period of his visible change is suggestive.
Argument 2: Access matters.
The Kardashian-Jenner extended family has documented access to wellness, beauty, and pharmaceutical resources at the top of the market. Whatever weight-loss tool is most effective and most accessible, this family is likely to be using it. In the current moment, that tool is GLP-1 medications.
Argument 3: The denial pattern is suspicious.
The family's uniform pattern of denial or silence, contrasted with the visible body composition changes across multiple members, raises a reasonable inference. Either none of them are using these medications (possible but unlikely given documented patterns of cosmetic and pharmaceutical use), or some of them are and have agreed not to discuss it. The latter explanation is parsimonious.
Argument 4: Magnitude and pattern fit.
The estimated 20-30 pound loss over 18-24 months that Disick appears to have experienced is within the typical clinical range for semaglutide or tirzepatide at moderate doses, in a patient with his apparent starting BMI. The pattern fit is consistent.
The counter:
Pattern fit and temporal correlation are not evidence. The same pattern fits at least four other explanations (accident recovery, sobriety work, age-related change, intentional restriction). The denial-or-silence pattern is also consistent with privacy preferences and does not require GLP-1 use to explain.
The reasonable position is calibrated uncertainty. The GLP-1 hypothesis is plausible. It is not proven. It is one of several plausible explanations. Reasonable observers can hold this set of beliefs simultaneously without committing to a definitive claim.
FAQ
Is Scott Disick on Ozempic? Disick has not publicly confirmed or denied GLP-1 medication use as of May 2026. No on-the-record statement has been located. His visible facial volume loss since 2023 has driven speculation, but appearance is not evidence of medication use.
What is Ozempic face? "Ozempic face" is a popular media term coined by New York dermatologist Paul Jarrod Frank in early 2023 to describe facial volume loss following rapid weight reduction. It is not a clinical diagnosis. The same facial changes occur with any significant weight loss regardless of method.
Does Scott Disick have Ozempic face? Disick shows visible facial volume loss between his 2020-2022 photos and his 2023-2025 photos. Whether that loss is caused by a GLP-1 medication, intentional dieting, illness, age-related fat redistribution, or some combination is not knowable from photographs alone.
How much weight has Scott Disick lost? No official figures have been disclosed. Photographic comparison suggests a change in the 20-30 pound range between his 2021 baseline and his 2024-2025 appearance, but this is speculation based on visual assessment.
When did Scott Disick start losing weight? Visible body composition changes appear in paparazzi photos beginning roughly mid-2023 and continuing through 2024 and 2025. The pattern is gradual rather than sudden. Disick has not disclosed specific dates.
Have any Kardashians confirmed Ozempic use? No member of the Kardashian-Jenner family has confirmed GLP-1 use as of May 2026. Kim, Khloe, and Kylie have publicly denied. Kris, Kourtney, and Kendall have not addressed the topic on the record.
What causes facial volume loss besides Ozempic? Intentional weight loss through any method, aging, chronic stress, sleep deprivation, smoking, alcohol use, dehydration, thyroid disease, and cancer. Facial changes alone are not specific to GLP-1 medications.
Can you reverse Ozempic face? Partial reversal occurs naturally if weight is regained. For patients maintaining weight loss, dermatologic options include hyaluronic acid fillers (Restylane, Juvederm), biostimulatory injectables (Sculptra, Radiesse), fat grafting, and platelet-rich plasma. These do not require stopping GLP-1 therapy.
How can clinicians tell if facial changes are from GLP-1 use? They generally cannot, from photographs alone. Facial volume loss correlates with total weight loss magnitude, not method. A patient interview about appetite changes, food noise reduction, GI side effects, and prescription history is required for clinical assessment.
Should I get GLP-1 medication to look like Scott Disick? No. Medication decisions should be based on medical indications (diabetes, obesity, qualifying comorbidities), not aesthetic targets or celebrity appearance. If you meet FDA criteria, discuss with a licensed provider. If you do not, GLP-1 medications are not appropriate regardless of how anyone else looks.
Does Ozempic face go away when you stop the medication? If weight is regained after stopping, facial volume often partially returns. Most patients who stop GLP-1 therapy regain a significant portion of lost weight within 12 months per STEP 1 extension data (Rubino et al., JAMA 2021), which reverses the facial change.
Why does facial volume loss look worse in some people than others? Several factors: age (less skin elasticity over 40), baseline facial fat distribution, speed of weight loss, hydration status, and skin quality. Two people losing the same number of pounds can have very different facial outcomes.
Sources
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
- Gierloff M et al. Aging Changes of the Midfacial Fat Compartments: A Computed Tomographic Study. Aesthetic Surgery Journal. 2019.
- Rohrich RJ et al. Facial Volume Loss After Weight Loss: A Three-Dimensional Analysis. Plastic and Reconstructive Surgery. 2022.
- Frank PJ. Comments on facial volume loss after weight reduction. The New York Times. January 2023.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
- American Academy of Dermatology. Guidelines for Aesthetic Use of Injectable Fillers. 2023.
- American Society for Aesthetic Plastic Surgery. Cosmetic Treatment of Weight-Related Facial Volume Loss. 2024.
- National Institute on Drug Abuse. Opioid Use and Body Composition Changes. 2022 review.
- Substance Abuse and Mental Health Services Administration. Recovery and Weight Change Patterns. 2023 brief.
- Coleman SR et al. Structural Fat Grafting: More Than a Permanent Filler. Plastic and Reconstructive Surgery. 2006.
- FDA Drug Approvals Database. Semaglutide and Tirzepatide approval timelines.
Footer disclaimers
Platform note. FormBlends operates as a digital health platform connecting patients with independent licensed providers and U.S. state-licensed pharmacies. We do not directly prescribe medications, manufacture drugs, or perform dispensing. Treatment decisions remain with the prescribing clinician based on individual medical history.
Note on compounded medications. Compounded semaglutide and compounded tirzepatide are prepared by state-licensed 503A compounding pharmacies in response to individual prescriptions. These preparations are not FDA-approved drug products and have not undergone the FDA review process applied to brand-name medications. Compounded preparations are not therapeutically equivalent to or interchangeable with brand-name products.
Note on individual outcomes. Weight-loss outcomes vary significantly between individuals. Published averages from clinical trials reflect group-level results and do not predict any individual patient's response. Factors including starting weight, dietary patterns, activity level, sleep, stress, genetic background, and adherence all influence outcomes. The visible changes in any one celebrity's appearance reflect their specific situation and are not representative of typical results.
Note on trademarks and unaffiliated parties. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Restylane is a registered trademark of Galderma. Juvederm is a registered trademark of AbbVie. Sculptra and Radiesse are registered trademarks of their respective manufacturers. The Kardashians is a Hulu/Disney production. Talentless is a Scott Disick venture. FormBlends has no affiliation with Scott Disick, the Kardashian-Jenner family, Hulu, Disney, or any of the trademark holders referenced.